Knowledge Hub
Knowledge Hub
Neuroendocrine Cancer New Zealand mourns the passing of Associate Professor Dr Malcolm Legget, a tireless advocate for NET patients.
It is with great sadness that we share the passing of Associate Professor Dr Malcolm Legget, a tireless advocate, clinician and friend to the New Zealand neuroendocrine cancer community.
From 2015, Malcolm and Siobhan Conroy spearheaded efforts to raise funds for a Gallium-68 generator. Alongside fellow clinicians, Malcolm pushed for PRRT access in New Zealand and championed better diagnosis and treatment pathways for NET patients.
From 2016, Siobhan, Malcolm and NECNZ turned to the problem of getting PRRT funded and delivered in New Zealand. COVID border closures were the catalyst for Auckland City Hospital and a New Zealand-based PRRT service finally being established.
Read the NZ Herald obituary for more on Malcolm's life and contribution.
Honouring a legacy: Malcolm Legget MNZM
Associate Professor Dr Malcolm Legget was awarded the MNZM for services to neuroendocrine cancer care in New Zealand.
Waikato clinicians publish rare renal NET case in international oncology journal
A Waikato Hospital and University of Auckland team co-authored a 2025 case report on a renal neuroendocrine tumour causing Cushing's syndrome, published in Case Reports in Oncology.
Gallium-68 Dotatate PET-CT scans now accessible onboard Mobile Imaging
Mobile Health Group and Mercy Radiology have rolled out Gallium-68 Dotatate PET-CT scans on a mobile imaging unit, bringing advanced NET diagnostics closer to home.
Lanreotide now funded in New Zealand for neuroendocrine tumours
From 1 March 2025 Pharmac funds lanreotide (Mytolac) for NETs and related conditions, giving Kiwis a second somatostatin analogue option.